248 related articles for article (PubMed ID: 19860732)
21. Assessing the chemical diversity of an hsp90 database.
Audisio D; Messaoudi S; Ijjaali I; Dubus E; Petitet F; Peyrat JF; Brion JD; Alami M
Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
23. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
24. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
25. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
[TBL] [Abstract][Full Text] [Related]
26. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Dutta Gupta S; Pan CH
Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
Mak OW; Sharma N; Reynisson J; Leung IKH
Bioorg Med Chem Lett; 2021 Apr; 38():127857. PubMed ID: 33609661
[TBL] [Abstract][Full Text] [Related]
28. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
[TBL] [Abstract][Full Text] [Related]
29. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors.
Lauria A; Ippolito M; Almerico AM
Comput Biol Chem; 2009 Oct; 33(5):386-90. PubMed ID: 19660987
[TBL] [Abstract][Full Text] [Related]
30. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
31. Discovery and development of heat shock protein 90 inhibitors.
Taldone T; Sun W; Chiosis G
Bioorg Med Chem; 2009 Mar; 17(6):2225-35. PubMed ID: 19017562
[TBL] [Abstract][Full Text] [Related]
32. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
33. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.
Kim HH; Hyun JS; Choi J; Choi KE; Jee JG; Park SJ
Sci Rep; 2018 Jan; 8(1):368. PubMed ID: 29321504
[TBL] [Abstract][Full Text] [Related]
34. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
35. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
[TBL] [Abstract][Full Text] [Related]
36. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
37. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
[TBL] [Abstract][Full Text] [Related]
38. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
39. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and evaluation of small molecule Hsp90 probes.
Taldone T; Zatorska D; Patel PD; Zong H; Rodina A; Ahn JH; Moulick K; Guzman ML; Chiosis G
Bioorg Med Chem; 2011 Apr; 19(8):2603-14. PubMed ID: 21459002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]